04:04 PM EDT, 08/01/2024 (MT Newswires) -- Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each rising 1%.

The iShares Biotechnology ETF (IBB) fell 0.5%.

In corporate news, Becton Dickinson ( BDX ) shares fell 2%. The company on Thursday trimmed its full-year organic revenue guidance after its fiscal Q3 sales fell short of Wall Street's expectations amid headwinds in China.

Eli Lilly ( LLY ) expects its Zepbound weight-loss drug to come out of its shortage in the US in the coming days, Chief Executive David Ricks told Bloomberg in an interview on Thursday. Separately, Eli Lilly ( LLY ) said Tirzepatide in a phase 3 trial showed statistically significant improvements in the reduction of heart failure risks as well as improvements in heart failure symptoms and physical limitations compared with a placebo. Its shares popped 3.4%.

Moderna ( MRNA ) shares tumbled 21%. The company reported better-than-expected Q2 results but lowered the full-year product sales guidance for its respiratory business amid growing competition in the US and low demand in the EU.

23andMe (ME) received a preliminary nonbinding indication of interest from Chief Executive Officer Anne Wojcicki to buy all 23andMe shares that she and her affiliates don't already own for $0.40 per class A or B share. The stock fell 4.3%.